U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H16N2.ClH.H2O
Molecular Weight 242.745
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPIDACRINE HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.NC1=C2CCCCC2=NC3=C1CCC3

InChI

InChIKey=SBTIBNSPYUUNGA-UHFFFAOYSA-N
InChI=1S/C12H16N2.ClH.H2O/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12;;/h1-7H2,(H2,13,14);1H;1H2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1998.tb00067.x/pdf

Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. Neuromidin has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system. Pharmacological action neuromidin is based on a combination of two mechanisms of action: blockade of potassium channels of the membrane of neurons and muscle cells; reversible inhibition of cholinesterase in synapses. Neuromidin enhances the effect on smooth muscle acetylcholine not only, but epinephrine, serotonin, histamine and oxytocin. It has the following pharmacological effects: - Improve and stimulate impulse conduction in the nervous system and neuromuscular transmission; - Enhances contractility of smooth muscle organs under the influence of acetylcholine agonists, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride; - Improves memory, slows progressive course of dementia. In preclinical studies Neuromidin is not teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic action, had no effect on the endocrine system

CNS Activity

Curator's Comment: Neuromidin (ipidacrine) has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Neuromidin

Approved Use

Unknown
Primary
Neuromidin

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
1997 May
Patents

Patents

Sample Use Guides

Dose and duration of treatment is determined individually depending on the severity of the disease. Peripheral nervous system diseases: 10-20 mg; 1-3 times a day. The treatment is 1 to 2 months. To prevent myasthenic crises, severe violations of neuromuscular conduction briefly parenterally administered 1-2 ml (15-30 mg) Neuromidin 1,5% solution for injection, and then continue treatment tablets Neuromidin, the dose can be increased to 20-40 mg; 5 times a day.
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
IPIDACRINE HYDROCHLORIDE MONOHYDRATE
MI  
Common Name English
1H-CYCLOPENTA(B)QUINOLIN-9-AMINE, 2,3,5,6,7,8-HEXAHYDRO-, MONOHYDROCHLORIDE, MONOHYDRATE
Common Name English
1H-CYCLOPENTA(B)QUINOLIN-9-AMINE, 2,3,5,6,7,8-HEXAHYDRO-, HYDROCHLORIDE, HYDRATE (1:1:1)
Systematic Name English
IPIDACRINE MONOHYDROCHLORIDE MONOHYDRATE
Common Name English
IPIDACRINE HYDROCHLORIDE MONOHYDRATE [MI]
Common Name English
IPIDACRINE HYDROCHLORIDE HYDRATE [JAN]
Common Name English
IPIDACRINE HYDROCHLORIDE HYDRATE
JAN  
Common Name English
Code System Code Type Description
CAS
118499-70-0
Created by admin on Sat Dec 16 06:02:25 GMT 2023 , Edited by admin on Sat Dec 16 06:02:25 GMT 2023
PRIMARY
SMS_ID
100000174702
Created by admin on Sat Dec 16 06:02:25 GMT 2023 , Edited by admin on Sat Dec 16 06:02:25 GMT 2023
PRIMARY
MERCK INDEX
m776
Created by admin on Sat Dec 16 06:02:25 GMT 2023 , Edited by admin on Sat Dec 16 06:02:25 GMT 2023
PRIMARY
EPA CompTox
DTXSID9046734
Created by admin on Sat Dec 16 06:02:25 GMT 2023 , Edited by admin on Sat Dec 16 06:02:25 GMT 2023
PRIMARY
PUBCHEM
6917941
Created by admin on Sat Dec 16 06:02:25 GMT 2023 , Edited by admin on Sat Dec 16 06:02:25 GMT 2023
PRIMARY
FDA UNII
OV96AIK79Q
Created by admin on Sat Dec 16 06:02:25 GMT 2023 , Edited by admin on Sat Dec 16 06:02:25 GMT 2023
PRIMARY